Cargando…

Pregnancy and Accelerated Phase of Myeloid Chronic Leukemia Treated with Imatinib: A Case Report from a Developing Country

Background. Chronic myeloid leukemia is a hematological malignancy caused by expression of BCR-ABL tyrosine kinase oncogene, product of the t(9;22) Philadelphia translocation. Accelerated phase of this disease marks the onset of advanced rapidly progressive disease unresponsive to many therapies. Pr...

Descripción completa

Detalles Bibliográficos
Autores principales:	Ngolet, Lydie Ocini, Kocko, Innocent, Elira Dokekias, Alexis
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Hindawi Publishing Corporation 2016
Materias:	Case Report
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4830715/ https://www.ncbi.nlm.nih.gov/pubmed/27123350 http://dx.doi.org/10.1155/2016/6104948

Ejemplares similares

Sickle-Cell Disease Healthcare Cost in Africa: Experience of the Congo
por: Ngolet, L. O., et al.
Publicado: (2016)

Routine Screening for Sickle Cell Disease during Pregnancy: Epidemiological and Haemoglobin Profile in Congo
por: Dokekias, Alexis Elira, et al.
Publicado: (2022)

Plasmocytome cutané secondaire révélant un myélome multiple: à propos d'un cas
por: Ngolet, Lydie Ocini, et al.
Publicado: (2016)

Addressing the Challenges to Diagnose Neonatal Hemolytic Anemia's Aetiologies in Low Ressources Countries: A Case Report
por: Ngolet, Lydie Ocini, et al.
Publicado: (2020)

Neonatal Screening for Sickle Cell Disease in Congo
por: Dokekias, Alexis Elira, et al.
Publicado: (2022)

Renal tuberculosis in an imatinib-treated chronic myeloid leukemia
por: Chandra, Abhilash, et al.
Publicado: (2020)

An uneventful pregnancy and delivery, in a case with chronic myeloid leukemia on imatinib
por: Martin, Jovita, et al.
Publicado: (2011)

Response to imatinib mesylate in childhood chronic myeloid leukemia in chronic phase
por: Linga, Vijay Gandhi, et al.
Publicado: (2014)

Imatinib in Chronic Myeloid Leukemia: an Overview
por: Sacha, Tomasz
Publicado: (2014)

Imatinib-Induced Tremor in a Patient with Chronic Myeloid Leukemia in Chronic Phase
por: Obeidat, Khaldun, et al.
Publicado: (2019)

Imatinib in chronic myeloid leukemia elderly patients
por: Gugliotta, Gabriele, et al.
Publicado: (2011)

Long-term efficacy and safety of dasatinib in patients with chronic myeloid leukemia in accelerated phase who are resistant to or intolerant of imatinib
por: Ottmann, Oliver, et al.
Publicado: (2018)

Concomitant AID Expression and BCL7A Loss Associates With Accelerated Phase Progression and Imatinib Resistance in Chronic Myeloid Leukemia
por: Yu, Nae, et al.
Publicado: (2017)

Dasatinib in the treatment of imatinib refractory chronic myeloid leukemia
por: Ramchandren, Radhakrishnan, et al.
Publicado: (2009)

Monitoring imatinib plasma concentrations in chronic myeloid leukemia
por: Martins, Darlize Hübner, et al.
Publicado: (2011)

Targeted treatment of chronic myeloid leukemia: role of imatinib
por: Tamascar, Ila, et al.
Publicado: (2009)

Therapy of Chronic Myeloid Leukemia: Twilight of the Imatinib Era?
por: Trela, Ewelina, et al.
Publicado: (2014)

Principal long-term adverse effects of imatinib in patients with chronic myeloid leukemia in chronic phase
por: Mughal, Tariq I, et al.
Publicado: (2010)

Efficacy and safety of generic imatinib after switching from original imatinib in patients treated for chronic myeloid leukemia in the United States
por: Abou Dalle, Iman, et al.
Publicado: (2019)

Celecoxib suppresses autophagy and enhances cytotoxicity of imatinib in imatinib-resistant chronic myeloid leukemia cells
por: Lu, Ying, et al.
Publicado: (2016)

Tuméfaction cervicale chez une enfant au CHU de Brazzaville, République du Congo
por: Elira Dokékias, Alexis, et al.
Publicado: (2023)

Peripheral neuropathy associated with imatinib therapy for chronic myeloid leukemia
por: Kavanagh, Simon, et al.
Publicado: (2018)

Leptin modification in chronic myeloid leukemia patients treated with imatinib: An emerging effect of targeted therapy.()
por: Mariani, Stefania, et al.
Publicado: (2013)

Incidence of second primary malignancies and related mortality in patients with imatinib-treated chronic myeloid leukemia
por: Gugliotta, Gabriele, et al.
Publicado: (2017)

Successful kidney transplantation in a patient with pre‐existing chronic myeloid leukemia treated with imatinib
por: Thiem, Ursula, et al.
Publicado: (2020)

Evaluation of the outcomes in patients with chronic myeloid leukemia treated with imatinib in 18-year follow-up
por: Aznab, Mozafar, et al.
Publicado: (2021)

Monitoring of BCR-ABL levels in chronic myeloid leukemia patients treated with imatinib in the chronic phase - the importance of a major molecular response
por: Machado, Melissa Pereira, et al.
Publicado: (2011)

Evaluation of anemia after long-term treatment with imatinib in chronic myeloid leukemia patients in chronic phase
por: Moura, Muriel Silva, et al.
Publicado: (2019)

Safety of bosutinib versus imatinib in the phase 3 BELA trial in newly diagnosed chronic phase chronic myeloid leukemia
por: Gambacorti-Passerini, Carlo, et al.
Publicado: (2014)

An economic analysis of high-dose imatinib, dasatinib, and nilotinib for imatinib-resistant chronic phase chronic myeloid leukemia in China: A CHEERS-compliant article
por: Wu, Bin, et al.
Publicado: (2017)

B-Cell Chronic Lymphocytic Leukemia with 11q22.3 Rearrangement in Patient with Chronic Myeloid Leukemia Treated with Imatinib
por: Lewandowski, Krzysztof, et al.
Publicado: (2016)

In vitro effects of imatinib on CD34(+) cells of patients with chronic myeloid leukemia in the megakaryocytic crisis phase
por: MENG, FANKAI, et al.
Publicado: (2014)

A case of subdural hematoma in patient with chronic myeloid leukemia treated with high-dose imatinib mesylate
por: Kim, Min Sik, et al.
Publicado: (2010)

Comparative study for the efficacy, safety and quality of life in patients of chronic myeloid leukemia treated with Imatinib or Hydroxyurea
por: Jain, Parveen, et al.
Publicado: (2013)

P-038: PREGNANCY OUTCOMES AMONG PATIENTS WITH SICKLE CELL DISEASE IN BRAZZAVILLE.
por: F., ATIPO-TSIBA GALIBA, et al.
Publicado: (2022)

Long‐term bosutinib for chronic phase chronic myeloid leukemia after failure of imatinib plus dasatinib and/or nilotinib
por: Cortes, Jorge E., et al.
Publicado: (2016)

PTCH1 is a reliable marker for predicting imatinib response in chronic myeloid leukemia patients in chronic phase
por: Alonso-Dominguez, Juan M., et al.
Publicado: (2017)

Safety and Efficacy of Elective Switch from Nilotinib to Imatinib in Newly Diagnosed Chronic Phase Chronic Myeloid Leukemia
por: Ibrahim, Ali, et al.
Publicado: (2022)

Therapeutic options for chronic myeloid leukemia: focus on imatinib (Glivec(®), Gleevec™)
por: Henkes, Martin, et al.
Publicado: (2008)

Synergy between Proteasome Inhibitors and Imatinib Mesylate in Chronic Myeloid Leukemia
por: Hu, Zheng, et al.
Publicado: (2009)

Cannot write session to /tmp/vufind_sessions/sess_1qpoqnn4gjldmn1bo5qrnejbmv